Phospholipase A₂ inhibitors promising in CHD

Coronary heart disease (CHD), resulting from the accumulation of atheromatous plaques within the coronary arteries, is the leading cause of death in the US. Phospholipase A₂ has been implicated in the pathogenesis of atherosclerosis, and research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) [Chicago, Illinois, US; March/April 2008] has demonstrated the efficacy of the phospholipase A₂ inhibitors darapladib and varespladib at reducing the activity of this enzyme.